Publications
Detailed Information
Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Ju-Yang | - |
dc.contributor.author | Lee, Eunyoung | - |
dc.contributor.author | Kim, Ji-Won | - |
dc.contributor.author | Suh, Chang-Hee | - |
dc.contributor.author | Shin, Kichul | - |
dc.contributor.author | Kim, Jinhyun | - |
dc.contributor.author | Kim, Hyoun-Ah | - |
dc.date.accessioned | 2023-10-10T00:31:12Z | - |
dc.date.available | 2023-10-10T09:39:30Z | - |
dc.date.issued | 2023-09-19 | - |
dc.identifier.citation | Arthritis Research & Therapy, Vol.25(1):174 | ko_KR |
dc.identifier.issn | 1478-6362 | - |
dc.identifier.uri | https://hdl.handle.net/10371/195676 | - |
dc.description.abstract | Background
While the availability of biological or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) has improved outcomes for rheumatoid arthritis (RA) patients, there remains a subset of individuals who fail to achieve low disease activity or remission despite multiple cycles of b/tsDMARDs. This state is referred to as 'difficult-to-treat (D2T)' RA. Methods Data from the Korean College of Rheumatology Biologics registry were utilized to analyze patients with RA who were treated with b/tsDMARDs. Results Among 2,321 RA patients with RA treated with b/tsDMARDs, 271 (11.7%) were diagnosed with D2T RA. Lower age (OR = 0.98, p < 0.001), longer disease duration (OR = 1.06, p < 0.001), lower patient global assessment (OR = 0.89, p = 0.045), higher SDAI (OR = 1.06, p = 0.014) and RAPID3 (OR = 1.06, p = 0.002), lower RF positivity (OR = 0.65, p = 0.04), and lower prior use of methotrexate (OR = 0.44, p = 0.008), sulfasalazine (OR = 0.59, p = 0.003), and leflunomide (OR = 0.67, p = 0.013) were associated with D2T RA. The drug survival rate of b/tsDMARDs did not differ between patients with D2T RA and non-D2T RA (p = 0.35). However, the drug survival of individual b/tsDMARD differed between patients with D2T RA and non-D2T RA after eight years. Patients with D2T RA withdrew from b/tsDMARDs due to inefficacy more frequently than those without D2T RA (p < 0.001). Conclusions D2T RA patients experienced higher disease activity despite maintaining b/tsDMARD therapy. Withdrawal rates due to inefficacy were higher in D2T RA. Effective therapeutic strategies are needed to improve disease control and treatment outcomes in this unique patient population. | ko_KR |
dc.description.sponsorship | The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a grant from Yuhan Corporation | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BMC | ko_KR |
dc.subject | Rheumatoid arthritis | - |
dc.subject | Difficult-to-treat | - |
dc.subject | Biologic therapy | - |
dc.subject | DMARDs | - |
dc.title | Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1186/s13075-023-03165-w | ko_KR |
dc.citation.journaltitle | Arthritis Research & Therapy | ko_KR |
dc.language.rfc3066 | en | - |
dc.rights.holder | BioMed Central Ltd., part of Springer Nature | - |
dc.date.updated | 2023-09-24T03:13:09Z | - |
dc.citation.volume | 25 | ko_KR |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.